Novavax announced Wednesday that the Food and Drug Administration (FDA) has placed a clinical hold on its application for a combination of Covid-19 and influenza vaccines, as well as its stand-alone flu vaccine. The hold comes after a report of nerve damage in a participant from a phase two trial completed last year. The biotech company is working with the FDA to resolve and resume the trials. The company’s stock plummeted nearly 20% following the news.
Category
🗞
NewsTranscript
00:00It's Benzinga bringing Wall Street to Main Street.
00:02Novavax announced Wednesday that the Food and Drug Administration has placed a clinical hold
00:07on its application for a combination COVID-19 and influenza vaccine as well as its standalone
00:12flu vaccine. The hold comes after a report of nerve damage in a participant from a phase 2
00:18trial completed last year. The biotech company is working with the FDA to resolve the issue
00:23and resume the trials. The company's stock plummeted nearly 20% following the news.
00:28For all things money, visit Benzinga.com slash GSTV.